$19.270
-0.208 (-1.08%)At close
SHC News
SHC Events
Sotera Health Q2 Revenue Reaches $321.38M, Exceeds Expectations
Reports Q2 revenue $321.38M, consensus $309.57M. "We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units," said Chief Executive Officer Alton Shader. "These results further underscore the essential nature of Sotera Health's offerings to healthcare. Since joining the Company, I have been impressed by the dedication of our teams, the trust our customers place in us and the industry-leading expertise that differentiates our business in highly regulated healthcare markets. Together, these strengths position us well to deliver consistent and reliable growth."
Consensus Raises FY26 Revenue Outlook to $1.24B
Consensus 97c. Narrows FY26 revenue view to $1.24B-$1.25B from $1.23B-$1.25B, consensus $1.24B. Raises FY26 adjusted EBITDA view to $634M-$643M from $632M-$641M. Shader continued, "Based on our strong first-half performance and confidence in the remainder of the year, we are raising our full-year 2026 outlook. I am excited about the numerous opportunities we have for growth as we continue to deepen our customer relationships, invest in our people, facilities and capabilities, and execute on our long-term strategy."
Goldman Sachs Sole Bookrunner, Deal Range $15.27-$15.43
The deal range was $15.27-$15.43. Goldman Sachs acted as sole book running manager for the offering.
Goldman Sachs Acts as Sole Book Running Manager for Offering
Goldman Sachs is acting as sole book running manager for the offering.
Sotera Health Company Launches Secondary Offering of 31.84M Shares
Sotera Health Company announced the launch of a secondary offering of 31.84M shares of its common stock. All 31.84M shares are being offered for sale by certain affiliates of Warburg Pincus and GTCR as selling stockholders. No other entities, and no individuals, are selling shares in the offering. The company is not offering any shares in the offering and will not receive any of the proceeds from the offering. Goldman Sachs & Co. is acting as the underwriter for the offering.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.